5 Key Takeaways

• 1

  Omadacycline and linezolid showed similar outcomes in a patient-centered analysis of 1,347 participants with acute bacterial skin infections.

• 2

  The DOOR framework ranked outcomes based on survival and three undesirable events, allowing evaluation of treatment benefits and harms together.

• 3

  About 80% of patients in both trials achieved the most desirable DOOR outcome, surviving without any prespecified undesirable events.

• 4

  The probability of a more desirable outcome with omadacycline was 50.6% in OASIS-1 and 52.1% in OASIS-2, indicating no significant treatment differences.

• 5

  The authors recommended future trials to incorporate DOOR and specific health-related quality-of-life instruments for better outcome distinction.